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Background.Pulmonaryarterialhypertension(PAH)isthemaincauseofmorbimortalityinsystemicsclerosis(SSc).IncreasedEng
expression has been demonstrated in SSc patients. Objective. Ascertaining serum levels of Eng in SSc patients with and without
elevated systolic pulmonary arterial pressure (sPAP) and comparing them with that of healthy volunteers. Methods. A cross-
sectional study was carried out. A commercial ELISA kit was used for measuring serum concentrations of Eng in 60 subjects:
40 patients with SSc with and without elevated sPAP, compared to 20 healthy control subjects. Elevated sPAP was detected by
echocardiogram. Results. No association between positive Eng and elevated sPAP was found when compared to the SSc without
elevated sPAP group (OR = 2.85; 0.65–12.88 95% CI; P = .11); however, an association was found between positive Eng and
elevated sPAP compared to healthy controls (OR = 23.22; 2.46–1050.33 95% CI; P = .001), and weak association was found
between the positive Eng with SSc without elevated sPAP group compared to healthy controls (OR = 8.14, 0.8–393.74 95% CI;
P = .046). Conclusion. Raised serum levels of Eng in SSc patients compared to healthy controls were found, suggesting a role for
Eng in SSc vasculopathy and not just in elevated sPAP. However, prospective studies are needed to verify such observations.
1.Introduction
Systemic sclerosis (SSc) is an autoimmune disease having
an unknown etiology characterized by microvasculopa-
thy, immunological abnormalities, and excessive collagen
deposits[1,2].Endothelialdysfunctionandmicrocirculation
damage are cardinal features of systemic sclerosis (SSc); it is
thoughtthatvascularchangesoccuratanearlystageandmay
include endothelial cell apoptosis, endothelium activation,
inﬂammatory cell recruitment, intimal proliferation, and
adventitial ﬁbrosis, all of which may lead to vessel oblitera-
tion [3].
AlthoughSScpathogenesisremainsuncertain,increasing
evidence suggests that transforming growth factor-beta
(TGF-β) plays a key role in tissue ﬁbrosis development, a
consequence of extracellular matrix accumulation in SSc
pathogenesis. TGF-β regulates diverse biological activities
including cell growth, apoptosis, diﬀerentiation, and extra-
cellular matrix synthesis through interaction with TGF-β
receptors [4, 5].
Endoglin (Eng) is a glycoprotein having antiangiogenic
propertiesthatactsasaT GF-βreceptorcomplexcomponent.
Eng may act on ﬁbroblasts to modulate TGF-β signaling by
acting as a molecular sink regulating or reducing the total
pool of TGF-β available for activating signal-transducing
receptors.
Increased expression in ﬁbroblasts and endothelial cells
has been demonstrated in SSc patients, suggesting that
deregulating Eng expression and/or function may be related
to the vascular manifestation of SSc [6, 7].
Pulmonary arterial hypertension (PAH) is the main
vascular complication in SSc, being an important cause of2 International Journal of Rheumatology
morbidity and the main cause of mortality, having 50%
survival rate at 12 months [8]. This vasculopathy is caused
by a number of soluble factors and involves a complex
interaction between endothelial cells, smooth muscle cells,
extracellularmatrix,coagulationfactors,andcirculatingcells
[9].
There are two types of PAH in SSc: PAH secondary to
ﬁbrosis and severe interstitial involvement and isolated PAH
without ﬁbrosis or interstitial lung disease, with the latter
reﬂecting the illness’ vascular pathology and resulting in a
more indolent pulmonary process [8].
PAH prevalence in SSc varies depending on the methods
used for diagnosis. Estimated PAH prevalence is 13.3%
when using echocardiogram [10]. Cardiac catheterization is
considered the gold standard for PAH diagnosis, but this
technique is invasive, expensive, and not available in all
centers. It can sometimes represent a high-risk factor for
morbidity; this is why its use for detecting PAH and its
followup are limited [11] .M a r k e r ss h o u l dt h u sb es o u g h tt o
enable detecting patient subgroups having the highest risk
of developing PAH as a vascular complication of SSc and
allowing followup. This would enable PAH to be diagnosed
as early as possible, thereby improving prognosis for PAH
and SSc patients.
This study examined serum levels of Eng in patients
with SSc and elevated sPAP (SSc-sPAP) and SSc without
elevatedsPAP(SSc-nonsPAP)andthesewerecomparedwith
healthy volunteers for determining any association between
Eng levels and elevated sPAP in SSc patients.
2.MaterialsandMethods
2.1. Patients. A cross-sectional study was carried out
between June and October 2008 during which 60 subjects
were analyzed; 40 patients met American College of Rheu-
matology (ACR) criteria [12] for SSc (20 patients had
elevated sPAP by echocardiogram and 20 patients did not),
and 20 control healthy subjects were also included. The
patients were consecutively selected based on the available
and willingness to participate in this study. Patients who
presented any other connective tissue disease or a con-
comitant pulmonary illness from any other etiology, work,
or environmental exposure for pulmonary disease were
excluded.
Registration forms were completed which included
demographic data, clinical characteristics, antibody levels,
reports from diagnostic tools such as echocardiogram
and high-resolution computed tomography of the thorax
(HRCTT).
The patients were subdivided into two groups: limited
SSc (lSSc) and diﬀuse SSc (dSSc) based on the limits
proposedbyLeRoyetal.[1].Bloodsamplesweredrawnfrom
the 40 SSc patients and from 20 healthy subjects matched by
age and gender. No patient was receiving calcium channel
blockers when being analyzed. All samples were stored at
−20
◦C until being processed. The protocol was approved by
the Universidad Nacional de Colombia’s ethics committee
and all patients signed the informed consent forms agreeing
to take part in this study.
2.2. Echocardiogram. All echocardiograms were taken by an
expert cardiologist using standard techniques for evaluating
right ventricle dimensions and tricuspid gradients after a
20-minute rest. The tricuspid systolic pressure gradient was
calculated by using Bernoulli’s modiﬁed equation [13].
2.2.1. Estimating Elevated Systolic Pulmonary Arterial Pres-
sure. The sPAP was calculated as being the sum of the
tricuspid gradient and estimated right atrial pressure. Ele-
vated sPAP was deﬁned in Colombian patients living at
2,600 meters above sea level as being mean >35mmHg
sPAP, >3m/second tricuspid regurgitation velocity, or
2.5m/second in patients having unexplained dyspnea [14].
ElevatedsPAPwasdeﬁnedas>35mmHg sPAP with HRCTT
withoutevidenceofinterstitial lung disease (suchasbibasilar
pulmonary ﬁbrosis or reticulonodular densities, being most
pronounced in the lung bases), or the presence of hetero-
geneous opacities such as reticular opacities, ground-glass
opacities, or honeycombing in HRCTT [14].
2.3. ELISA. A commercial ELISA kit (R&D Systems, Min-
neapolis, Minn, USA) was used for serum measurement for
Eng from SSc patients and the control group, following the
manufacturer’s protocol. Each sample was done twice.
2.4. Statistical Analysis. STATA 9.0 software was used for
statistical analysis. The Shapiro-Wilks test was used for
evaluating data distribution. Clinical data, elevated sPAP and
Eng serum values were compared by unpaired Student t-test
or Mann-Whitney U test as appropriate. Fisher’s exact test
or Chi-2test was used for determining association between
categorical variables. Odds ratios (OR) with 95% conﬁdence
interval(95%CI)werealsoreported.TheKruskal-Wallistest
or ANOVA was used for intergroup analysis, as appropriate.
The Spearman test was used for calculating the correlation
between sPAP and Eng levels. Two standard deviations (SD)
above mean were taken for calculating positive Eng values.
P<. 05 was considered signiﬁcant for all analysis.
3. Results
The study included 60 subjects, 40 having a diagnosis of SSc
and 20 healthy control subjects (20 SSc-sPAP patients and
20 SSc-non sPAP patients). In the SSc group, 26 patients
presented lSSc and 14 patients dSSc; 28 were female and 12
were men, having an average age of 44.3 ± 9.8 at disease
onset.
Diseasedurationwas8.57 ±5.2years,measuredfromthe
point at which the ﬁrst symptom appeared. The time from
the onset of Raynaud’s phenomenon was 9.5 ± 5.9 years and
Rodnan’s score [15] was 21.7 ± 10.2. All patients presented
telangiectasias; 12 (30%) patients had calcinosis, 28 (70%)
patients had gastrointestinal involvement, and mean sPAP
value was 57.75 ± 14.5mmHg in SSc-sPAP patients. Sixteen
patients from the SSc-sPAP group (16/20) were diagnosed
with > 35mmHg sPAP and >3 m/second tricuspid regurgi-
tation velocity; only four (4/20) had >3m/second tricuspid
regurgitation velocity. Sixteen SSc-sPAP patients (80%) hadInternational Journal of Rheumatology 3
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Figure 1: Eng levels in SSc with elevated sPAP, without elevated
sPAP, and in healthy controls. Serum levels of Eng in patients with
SSc and elevated sPAP, SSc without elevated sPAP, and healthy
control subjects (mean ± SE). Mean serum levels were statistically
higherintheSScgroupcomparedtothecontrolgroup(SScgroupcf
healthy controls P = .0028; SSc with elevated sPAP cf SSc without
elevated sPAP ∗P = .2447; SSc without elevated sPAP cf healthy
controls ∗∗P = .057; SSc with elevated sPAP cf healthy controls
∗∗∗P = .0006).
>48mmHg sPAP and four (20%) had <48mmHg sPAP
but more than 40mmHg in sPAP and had no signiﬁcant
structural right atrial and/or ventricular damage. Forty-ﬁve
percent had calcinosis in the SSc-sPAP group, whereas only
15% were present in SSc-non sPAP group (P = .041).
HRCTT revealed no ILD-related ﬁndings in any patient.
No abnormality was found in 12 patients (60%) and PAH
ﬁndings such as dilatation of proximal and segmental
pulmonary arteries were found in 8 (40%). No patients had
bilateral reticular linear or reticulonodular densities in the
lung bases or opacities reticular, ground-glass opacities, or
honeycombing in HRCTT.
Anticentromere antibodies (ACA) were reported to be
positive in 27 patients (67.5%) and anti-Scl-70 in 9 patients
(22.5%). Seventy-ﬁve percent had positive ACA in the
SSc-sPAP group (5/7 having diﬀuse SSc and 10/13 having
limited SSc), whereas antibodies anti-Scl-70 were positive
in 10% of that group (2/7 SSc-sPAP patients and diﬀuse
SSc). A speckled antinuclear antibody (ANA) pattern was
present in 15% (3/13 SSc-sPAP patients and limited SSc). No
patient presented renal crisis or ischemic cutaneous ulcers,
but all presented telangiectasias. Table 1 gives the clinical
characteristics for the SSc patients.
Serum levels of Eng in SSc-sPAP patients tended to be
higher than in SSc-non sPAP patients, having no signif-
icant statistical diﬀerence (P = .2447) and were higher
than healthy controls (P = .0006). Mean values were
6.89ng/dL, 6.20ng/dL, and 5.42ng/dL and median values
were 7.07ng/dL, 6.01ng/dL, and 5.42ng/dL, respectively
(Figure 1).
TherewasnodiﬀerencebetweentheSSc-nonsPAPgroup
and healthy controls (P = .057). Intergroup analysis revealed
Table 1: SSc patients’ clinical characteristics.
Clinical characteristics SSc- sPAP
patients
SSc-non
sPAP patients P
n = 20 n = 20
Age (in years) 54.4 ±11 51.1 ±13.7. 4
Age at onset 44.75 ±10 43.9 ± 9. 7 8
Male:female 2.3:1 2.3:1 1
Duration (means ± SD),
years 9.65 ±47 .5 ±6.3. 1 9
lSSc 13 13 1
dSSc 7 7 1
sPAP mmHg at rest 57.75 ±14.51 9 .4 ±12 <.0001
Raynaud% 100 100 1
Time of onset of
Raynaud 9.1 ±49 .95 ± 6. 8 1
Rodnan score 22.1 ±92 1 .3 ±10 .21
Calcinosis% 45 15 .041
Telangiectasias% 100 100 1
Renal crisis% 0 0
Ischemic cutaneous
ulcers% 00
Gastrointestinal
involvement% 60 80 .15
normal HRCTT% 60 100 NS
HRCTT PAH% 40 0 NS
Anticentromere ab% 75 60 .21
Anti-Scl-70 ab% 10 20 NS
ANA% 15 20 NS
Methotrexate 11 11 1
Cyclophosphamide 6 7 .73
SD: standard deviation, lSSc: limited systemic sclerosis, dSSc: diﬀuse sys-
temic sclerosis, sPAP: systolic pulmonary arterial pressure, HRCTT: high-
resolution computed tomography of thorax, PAH: pulmonary arterial hy-
pertension. Fisher’s or Wilcoxon test was used for calculating the diﬀerences
between groups.
ad i ﬀerence between the three groups (Kruskal-Wallis test,
P = .0037) which was mainly due to SSc-sPAP group
compared to the healthy control group. Categorized analysis
o fs e r u ml e v e l sf r o mE n gr e p o r t e dad i ﬀerence between
all groups (P = .003); however, detailed analysis revealed
interesting ﬁndings. The SSc-sPAP group consisted of eleven
patients having positive Eng (OR = 2.85; 0.65–12.88 95%
CI; P = .11, when was compared to the SSc-non sPAP
group); the SSc-non sPAP group had six patients (OR =
8.14; 0.8–393.74 95% CI; P = .046, when compared to
healthycontrols)andonehealthycontrol(OR = 23.22;2.46–
1050.33 95% CI; P = .001 when was compared to the SSc-
PAH group). An association was reported for positive Eng
(OR = 14.04; 1.79–617.05 95% CI; P = .0028) when SSc-
sPAP and SSc-non sPAP groups were pooled and compared
to healthy controls. There was no correlation between Eng
levels and sPAP (Rho = 0.1384,P = .39).4 International Journal of Rheumatology
4. Discussion
Two clinical hallmarks for SSc are its clinical heterogeneity
and the wide range of vascular and ﬁbrotic manifestations.
Organ involvement, diﬀerent patterns, and internal organ
manifestation severity are the global outcome’s most signiﬁ-
cant determinants [16].
PAH is the main cause of morbidity and mortality
amongst vascular complications for SSc. A diagnosis of PAH
has occurred late in the course of the disease until now and
right heart catheterization has been the gold standard for
its diagnosis. However, this diagnosis test is invasive and
implies morbidity and mortality risks. The echocardiogram
is a noninvasive technique and its limitations include it being
operator-dependent and its false positive rate is close to 30%
[16].
An imbalance in circulating angiogenic factors in SSc
may be associated with vascular endothelial dysfunction.
Eng is one of the factors supporting vascular integrity, with
this being a 180kDa homodimeric coreceptor for TGF-β
superfamily members which is predominantly expressed on
endothelial cell surfaces [17].
Eng may have roles in hematopoiesis, cardiovascular
development, and angiogenesis and is highly expressed on
vascular endothelial cells [18], chondrocytes [19], and term
placentasyncytiotrophoblasts[20].Itisalsofoundonmono-
cytes [21], erythroid precursors [22], and a hematopoietic
stem cell subpopulation [23]. Although its role remains
elusive, circulating soluble Eng levels are raised in patients
suﬀering from atherosclerosis [24] and certain cancers
including breast [25], colon [26], and myeloid malignancies
[27]. Eng is likely to be involved with angiogenesis in
endothelial cells, since prominent Eng expression has been
demonstrated in neovascular states, including the enhanced
vascularity of psoriasis [28].
Previous reports have shown that the Eng gene is
located at 9q34.1 and that mutations of this gene having
reduced Eng expression are responsible for one of the two
types of hereditary hemorrhagic telangiectasia, an autosomal
dominant disorder characterized by multiple telangiectasia
of the skin, mucous membranes, gastrointestinal tract,
arteriovenous malformation, and pulmonary hypertension
[29].
Leask et al. [6] found that the endothelial-enriched
high-aﬃnity TGF-β receptor endoglin was up-regulated in
dermis ﬁbroblasts cultured from involved areas of skin taken
from SSc patients related to normal ﬁbroblasts and that
Eng expression increased with the disease’s progression,
suggesting that Eng might represent a potential marker for
staging SSc. Another ﬁnding was that Eng overexpression
in ﬁbroblasts blocked the accumulation of activated nuclear
Smads and suppressed TGF-β ability to induce connective
tissue growth factor (CTGF) proﬁbrotic cytokine target
gene promoter. Such results suggest that SSc ﬁbroblasts
induce Eng expression to suppress TGF-β induction of gene
expression in a negative feedback loop.
Fujimoto et al. [30] examined soluble Eng serum levels
in SSc patients and found these levels to be higher in patients
having lSSc, telangiectasias, and ACA. Furthermore, SPPA
was positively correlated with Eng levels in patients having
lcSSc, but only two of these patients presented PAH. There
was no diﬀerence in heart, esophageal, or renal involvement
between patients having higher Eng serum levels and those
having normal levels.
Wipﬀ et al. [17] demonstrated an association between
Eng gene polymorphism and PAH, and another study by the
same authors [31] found that Eng appeared to be increased
in SSc and to be particularly associated with the vascular
phenotype. They also showed a higher Eng concentration in
SSc patients compared to healthy controls; they included 17
PAHpatientsandfoundthatEngserumlevelsinSScpatients
with PAH were similar to those of patients without PAH.
Higher Eng levels were found in SSc patients compared to
healthy controls in a previous study by the present group
[32],havingastatisticaldiﬀerencebetweenthetwogroupsin
favor of SSc and PAH patients. However, a correlation with
sPAP value was not found, with a limitation of this study
beingthelackthecomparisonwithpatientswithSScwithout
PAH.
Higher Eng levels were found in the two types of SSc in
the current study, contrasting with the results of Fujimoto
et al. [30]. The 20 patients in the current study presented
elevated sPAP secondary to SSc, and Eng levels in these
were more raised than in controls (SSc-non sPAP group and
healthycontrols).However,therewasnostatisticaldiﬀerence
when the SSc-sPAP group was compared to the SSc-non
sPAP group. These results diﬀered from the recent ones
reported by Wipﬀ et al. [17] and suggest that Eng serum
levels are elevated in SSc patients and not exclusively due
to PAH. Endothelial activity in patients in the early stages
of PAH may be a potential reason for ﬁnding elevated Eng
serum levels. The diﬀerence in calcinosis percentage between
the groups is striking, especially since calcinosis may develop
inareasofpoorperfusionandbetheresultofvasculardisease
[33].
Anotherinterestingﬁndinginthisstudywasthepresence
of ACA in diﬀuse SSc. ACA have been associated with
limitedSScandanti-topoisomeraseIwithdiﬀuseprogressive
disease; however, 10 to 15 percent of patients with diﬀuse
disease have these antibodies [34]. Coral et al. [35]r e p o r t e d
positive ACA in 93% of patients studied in Colombia,
independent of SSc subtype.
It thus seems that the higher presence of positive
ACA could be related to PAH; in fact earlier reports have
associated these antibodies with increased risk of pulmonary
hypertension [36, 37]. Telangiectasias were present in all
patients in the present study; it had already been reported
in Colombian SSc patients [35].
This work had the following limitations. Right heart
catheretization (RHC) is now considered the gold standard
for PAH diagnosis due to the presence of high false positive
results with echocardiogram and also because RHC allows
therapeutic choices for vasoreactivity seen in PAH to be
evaluated. Elevated sPAP was assessed and diagnosed with
echocardiogram in this work due to the Colombian Health
System’s limitations regarding performing RHC. There was a
high correlation between the measurements obtained using
both techniques when the cardiologist operator had broadInternational Journal of Rheumatology 5
experience in evaluating pulmonary arterial pressure and
there was no change in right heart anatomical structural.
Besides,>48mmHgsPAPassociatedwith>3.0TRVwasused
for diagnosing moderate/severe PAH [38], thereby reducing
the possibility of false positives occurring. Since our cohort
had been continuously followed up, the cases were chosen
during the early phases of PAH development to exclude
even the smallest structural damage that could have altered
echocardiographic evaluation.
A second limiting concerned the fact that a relative
small population was included in each branch to include
biomarkers having a potentially pathophysiologic role for
generating elevated sPAP and because not enough scientiﬁc
papers have assessed it, meaning that the current paper can
be considered to be a pilot-study.
5. Conclusion
Raised Eng serum levels were found in SSc patients (SSc-
sPAP patients and SSc-non sPAP) compared to healthy con-
trols, suggesting a role for Eng in SSc vasculopathy and not
just in PAH. However, prospective studies are needed which
include a larger population to verify these observations.
Serum biomarkers could detect an early stage of the disease
in patients having a high risk of developing elevated sPAP
which could aﬀord a better outcome during these patients’
follow up.
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